Skip to main content

Spectrum: Autism Research News


Michael Ehlers

Neuroscience Chief Scientific Officer, Pfizer

April 2014

A cautionary tale for autism drug development

by  /  15 April 2014

Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.

November 2013

SHANK mutations converge at neuronal junctions in autism

by ,  /  5 November 2013

SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.

October 2012

Drug zone

by  /  26 October 2012

Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.